Valuation: Evolus, Inc.

Market Cap 50Cr 43Cr 40Cr 37Cr 70Cr 4.77TCr 71Cr 475.12Cr 186.48Cr 2.39TCr 188.26Cr 184.14Cr 7.91TCr P/E 2026 *
-14.5x
P/E 2027 * -47.9x
Enterprise Value 63Cr 54Cr 51Cr 47Cr 88Cr 5.98TCr 89Cr 595.48Cr 233.72Cr 3TCr 235.95Cr 230.78Cr 9.91TCr EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.62x
Free-Float
83.41%
Yield 2026 *
-
Yield 2027 * -
1 day+2.43%
1 week+29.97%
Current month+29.97%
1 month+11.78%
3 months+19.34%
6 months+68.67%
Current year+14.14%
1 week 5.84
Extreme 5.835
7.8
1 month 5.44
Extreme 5.445
7.8
Current year 3.86
Extreme 3.86
7.8
1 year 3.86
Extreme 3.86
7.95
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Executive Officer

2,51,698 0.3891%
17/02/26 Free

Chief Financial Officer

4,20,449 0.6500%
17/02/26 Free

Chief Technology Officer

3,28,475 0.5078%
Change 5-day change 1-year change 3-year change Capi.($)
+2.43%+29.97%+28.64%-19.26% 50Cr
-0.52%+3.21%+89.52%+127.32% 1,05700Cr
+0.88%+1.13%+49.56%+49.69% 62TCr
+0.89%-1.95%+24.23%+64.44% 43TCr
+0.71%+3.87%+49.07%+37.85% 36TCr
+0.64%-0.49%+33.94%+40.01% 30TCr
+0.39%-5.83%+8.92%+7.85% 25TCr
+1.51%+6.69%+42.58%+57.57% 22TCr
+3.92%-0.46%-5.56%-52.32% 21TCr
+1.80%+2.30%+11.56%+66.35% 17TCr
Average +1.27%+3.78%+33.25%+37.95% 36.21TCr
Weighted average by Cap. +0.66%+1.22%+48.72%+64.62%

Financials

2026 *2027 *
Net sales 33Cr 29Cr 27Cr 25Cr 46Cr 3.17TCr 47Cr 315.99Cr 124.03Cr 1.59TCr 125.21Cr 122.47Cr 5.26TCr 39Cr 34Cr 32Cr 29Cr 55Cr 3.72TCr 55Cr 370.72Cr 145.5Cr 1.87TCr 146.89Cr 143.67Cr 6.17TCr
Net income -3.74Cr -3.23Cr -3.02Cr -2.77Cr -5.21Cr -355.47Cr -5.29Cr -35Cr -14Cr -178.17Cr -14Cr -14Cr -589.02Cr -1.09Cr -93.95L -87.74L -80.49L -1.51Cr -103.37Cr -1.54Cr -10Cr -4.04Cr -52Cr -4.08Cr -3.99Cr -171.29Cr
Net Debt 13Cr 11Cr 10Cr 9.41Cr 18Cr 1.21TCr 18Cr 120.36Cr 47Cr 605.82Cr 48Cr 47Cr 2TCr 13Cr 11Cr 11Cr 9.78Cr 18Cr 1.26TCr 19Cr 125.1Cr 49Cr 629.67Cr 50Cr 48Cr 2.08TCr
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
07/26/07 $7.590 +2.43% 16,31,994
06/26/06 $7.410 +19.90% 29,19,902
05/26/05 $6.180 +0.98% 11,60,783
04/26/04 $6.120 +1.16% 6,68,341
03/26/03 $6.050 +3.60% 5,87,133
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.590USD
Average target price
14.67USD
Spread / Average Target
+93.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock